About Us

Manufacturing‑led implant‑grade materials, built for OEM projects

Hongkong Kannry Industrial Co., Ltd. (Kannrybio) is a specialised manufacturer of medical‑grade bioactive inorganic materials and surgical implant materials. Manufacturing is based in mainland China; sales and customer support are headquartered in Hong Kong.

ISO 13485

Class III + Class II manufacturing licenses

Zirconia blocks registration

Verified physicochemical & biological performance

3,000+ m² facility

150+ tons / month capacity

What we make

CaP · Silicates · Bioactive glass · CaSO₄ · CPC systems

What we control

PSD · BET · phase purity · impurity profile

How we support

Customization · evaluation · prototypes · OEM collaboration

Where we operate

Mainland China manufacturing · Hong Kong sales & support

Core advantages (fast scan)

Manufacturing scale

3,000+ m² production facility; monthly capacity 150+ tons for stable OEM supply.

Comprehensive portfolio

Calcium phosphate, calcium silicate, bioactive glass and calcium sulfate systems; nano → macro forms.

Customization first

Multi‑dimensional customization across particle size, BET, pore structure and morphology, plus technical service.

Strong R&D capability

80%+ technical team with master’s/doctoral degrees; experience spanning synthesis, characterization and translation.

Rigorous quality & compliance

ISO 13485 QMS, Class III + II manufacturing licenses, zirconia blocks registration, standardized documentation.

Verified performance

Physicochemical and biological performance verified by CFDA‑authorized institutions; support files available for OEM projects.

Factory photos (placeholders)

Certificates & licenses (placeholders)

Company profile

Who we are · What we make · Licenses & certification · Patents & awards

Hongkong Kannry Industrial Co., Ltd. is a specialised manufacturer dedicated to the research, production, and global application of medical‑grade bioactive inorganic materials and surgical implant materials. With a focus on high‑performance biomedical ceramics, calcium phosphate, calcium silicate, and composite bone repair materials, Kannry upholds the mission of “Innovation Empowers Medicine, Materials Reshape the Future.” We are committed to promoting the international development of bio‑inorganic materials and providing safer, more stable, and more advanced solutions for the global orthopedic, dental, aesthetic, and tissue regeneration industries.

Manufacturing: mainland China · Sales & customer support: Hong Kong · Facility: 3,000+ m² · Capacity: 150+ tons / month

Licenses & certification

Class III + Class II medical device manufacturing licenses (implant materials & prosthetic ceramics).
ISO 13485 Medical Device Quality Management System certification.
Zirconia ceramic dental blocks registration certificate.
α‑TCP: ISO international standard adoption mark certificate; corporate standard Q/DA 006‑2017 (α‑TCP / TTCP for surgical implants).
Physicochemical and biological performance verified by CFDA‑authorized institutions (materials & evaluation support available).

Patents & awards

Authorized invention patents: 8 (China), 11 (United States), 1 (India); 3 PCT protections; 20+ pending patents worldwide.
Innovation awards for key technologies (e.g., bioactive ceramic bone scaffolds; HA whiskers for dentistry & orthopedics).
Participation in standardization work for α‑TCP and TTCP recognized by international standardization bodies.

Product overview

What we industrialize · Product families · Forms & morphologies · Typical users

Kannry is dedicated to the industrialization of core technologies and key products within the high‑end orthopedic implant materials supply chain. We have established advanced R&D and production bases for composite ceramic femoral heads, zirconia blocks for all‑ceramic dental prosthetics, calcium phosphate bioactive materials, high‑performance orthopedic implants, and medical‑grade injectable aesthetic fillers.

Material systems

Calcium phosphate: α‑TCP, β‑TCP, HA (micro/nano/whisker), TTCP, OCP and related systems.
Silicates & glasses: calcium silicate and 45S5 bioactive glass systems.
Calcium sulfate systems, CPC powders/kits and porous scaffold concepts.

Forms & customization

Micro / sub‑micron / nano; spherical, rod‑like, plate‑like, whisker and fibrous morphologies.
Customization across PSD, BET, pore structure and morphology, aligned to processing windows and targets.

Products are supplied to universities, research institutes, hospitals and biomedical enterprises worldwide, supporting both R&D and OEM programs.

Core advantages

Portfolio · R&D · Quality · Customization · Services

Comprehensive product portfolio — Multiple material systems including calcium phosphate, calcium silicate, bioactive glass and calcium sulfate, covering nano to macroscopic structural levels.
Strong R&D capability — 80%+ of the technical team holds master’s or doctoral degrees; core members have participated in international standardization research.
Rigorous quality system — ISO 13485 QMS with documented change control, batch‑to‑batch stability and analytical verification.
Innovative customization services — Multi‑dimensional customization across particle size, specific surface area, pore structure and morphology with tailored technical support.
Evaluation & preclinical support — Physicochemical testing, biological evaluation support, animal study support and prototype development for OEM projects.

Corporate culture

Mission · Vision · Core values · Team · Sustainability

At Hongkong Kannry Industrial Co., Ltd., our culture is built on integrity, innovation, and precision, reflecting our commitment to human health and advanced biomedical technology.

Mission — Innovation Empowers Medicine, Materials Reshape the Future
Vision — A Global Leader in Bio‑Inorganic and Regenerative Materials
Core values — Integrity · Innovation · Excellence · Collaboration · Responsibility
Team — Experts across biomaterials, chemistry, medicine, and materials engineering; collaborative and clinical‑oriented work style.
Sustainability — Green manufacturing mindset and responsible development to support long‑term healthcare impact.